NZ748771A - Pharmaceutical compositions comprising nitroxyl donors - Google Patents

Pharmaceutical compositions comprising nitroxyl donors

Info

Publication number
NZ748771A
NZ748771A NZ748771A NZ74877114A NZ748771A NZ 748771 A NZ748771 A NZ 748771A NZ 748771 A NZ748771 A NZ 748771A NZ 74877114 A NZ74877114 A NZ 74877114A NZ 748771 A NZ748771 A NZ 748771A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical compositions
nitroxyl donors
hydroxysulfonamide type
compositions
nitroxyl
Prior art date
Application number
NZ748771A
Other languages
English (en)
Inventor
Vincent Jacob Kalish
Frederick Arthur Brookfield
Stephen Martin Courtney
Lisa Marie Frost
John Toscano
John Reardon
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of NZ748771A publication Critical patent/NZ748771A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ748771A 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors NZ748771A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14
NZ709986A NZ709986A (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors

Publications (1)

Publication Number Publication Date
NZ748771A true NZ748771A (en) 2019-12-20

Family

ID=50064795

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ748771A NZ748771A (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors
NZ709985A NZ709985A (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index
NZ748769A NZ748769A (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index
NZ709986A NZ709986A (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ709985A NZ709985A (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index
NZ748769A NZ748769A (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index
NZ709986A NZ709986A (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors

Country Status (29)

Country Link
US (13) US10245249B2 (OSRAM)
EP (5) EP3284463B1 (OSRAM)
JP (5) JP6533159B2 (OSRAM)
KR (2) KR102177899B1 (OSRAM)
CN (4) CN105142627B (OSRAM)
AU (5) AU2014207404B2 (OSRAM)
BR (2) BR112015017251B1 (OSRAM)
CA (2) CA2898445C (OSRAM)
CY (3) CY1120535T1 (OSRAM)
DK (3) DK2945621T3 (OSRAM)
ES (4) ES2659969T3 (OSRAM)
HK (1) HK1251170B (OSRAM)
HR (3) HRP20180121T1 (OSRAM)
HU (3) HUE036589T2 (OSRAM)
IL (4) IL239906B (OSRAM)
LT (3) LT2945621T (OSRAM)
MX (2) MX373176B (OSRAM)
NZ (4) NZ748771A (OSRAM)
PL (3) PL2945620T3 (OSRAM)
PT (3) PT2945620T (OSRAM)
RS (3) RS58174B1 (OSRAM)
RU (3) RU2684916C2 (OSRAM)
SG (6) SG10201913286PA (OSRAM)
SI (3) SI2945620T1 (OSRAM)
SM (3) SMT201900575T1 (OSRAM)
TR (1) TR201802211T4 (OSRAM)
TW (3) TWI712409B (OSRAM)
WO (2) WO2014113700A1 (OSRAM)
ZA (2) ZA201505090B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368352B (es) 2006-03-17 2019-09-30 Univ Johns Hopkins Derivados de n-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiologicamente utiles.
HK1200168A1 (en) 2011-10-17 2015-07-31 The Johns Hopkins University Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
PT2945620T (pt) 2013-01-18 2018-02-21 Cardioxyl Pharmaceuticals Inc Dadores de nitroxilo com índice terapêutico melhorado
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2017041701A1 (zh) 2015-09-07 2017-03-16 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
KR20180070672A (ko) 2015-10-19 2018-06-26 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 n-히드록실술폰아미드 유도체
JP6889704B2 (ja) 2015-10-19 2021-06-18 カルディオキシル ファーマシューティカルズ，インク． ニトロキシルドナーとしてのピラゾロン誘導体
KR20190070912A (ko) 2016-07-28 2019-06-21 더 존스 홉킨스 유니버시티 O-치환된 히드록삼산
US11083704B2 (en) * 2017-01-03 2021-08-10 Bristol-Myers Squibb Company Method of administering nitroxyl donating compounds
BR112019021910A2 (pt) * 2017-04-18 2020-05-26 Genfit Combinação de elafibranor ou derivados do mesmo com um agente anti-nash, antifibrótico ou anticolestático
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
CA2181581A1 (en) * 1994-01-19 1995-07-20 Jan Bron Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
EP1026162A4 (en) 1997-10-24 2001-01-17 Shionogi & Co ANTI-RHUMATISMAL AGENT
DE69906397T2 (de) * 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
AU4333799A (en) 1998-06-04 1999-12-20 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6638534B1 (en) 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
SG128491A1 (en) 2000-12-13 2007-01-30 Wyeth Arqule Inc Heterocyclic sulfonamide inhibitors of beta amyloid production
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
US20090298795A1 (en) 2005-06-23 2009-12-03 The Johns Hopins University Thiol-Sensitive Positive Inotropes
MX368352B (es) 2006-03-17 2019-09-30 Univ Johns Hopkins Derivados de n-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiologicamente utiles.
EP2010476A4 (en) 2006-04-13 2011-01-26 Univ Wake Forest Health Sciences NITROXYL DISPENSERS FROM C-NITROSO COMPOUNDS
BRPI0817562A2 (pt) 2007-09-26 2017-05-02 Cardioxyl Pharmaceuticals Inc derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
WO2009137717A1 (en) 2008-05-07 2009-11-12 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CA2782110A1 (en) 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
JP5832447B2 (ja) 2009-12-07 2015-12-16 ザ ジョンズ ホプキンス ユニバーシティ ビスアシル化ヒドロキシルアミン誘導体
HK1200168A1 (en) 2011-10-17 2015-07-31 The Johns Hopkins University Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
EP2914579A1 (en) 2012-11-01 2015-09-09 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
PT2945620T (pt) * 2013-01-18 2018-02-21 Cardioxyl Pharmaceuticals Inc Dadores de nitroxilo com índice terapêutico melhorado
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
HK1251170B (en) 2020-04-09
KR102177899B1 (ko) 2020-11-12
AU2014207404B2 (en) 2017-10-19
NZ709986A (en) 2020-01-31
KR20150108879A (ko) 2015-09-30
US20220193026A1 (en) 2022-06-23
SMT201800088T1 (it) 2018-03-08
SMT201900027T1 (it) 2019-02-28
US10517847B2 (en) 2019-12-31
ES2882279T3 (es) 2021-12-01
IL239906A0 (en) 2015-08-31
EP3427728B1 (en) 2021-07-07
US10213408B2 (en) 2019-02-26
SG10201802855TA (en) 2018-05-30
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
BR112015017241A8 (pt) 2019-10-29
US9156804B2 (en) 2015-10-13
US20190133990A1 (en) 2019-05-09
JP6801045B2 (ja) 2020-12-16
HK1216858A1 (en) 2016-12-09
JP2016510326A (ja) 2016-04-07
AU2018203240B2 (en) 2019-12-12
DK2945621T3 (en) 2019-02-11
US10792273B2 (en) 2020-10-06
RU2684916C2 (ru) 2019-04-16
US20150175566A1 (en) 2015-06-25
US11273143B2 (en) 2022-03-15
PL2945621T3 (pl) 2019-05-31
JP6311038B2 (ja) 2018-04-11
BR112015017251A8 (pt) 2019-10-29
AU2014207408C1 (en) 2018-09-06
DK2945620T3 (en) 2018-02-05
PT3284463T (pt) 2019-10-30
CA2898445C (en) 2022-05-03
EP2945620B1 (en) 2017-11-22
ES2659969T3 (es) 2018-03-20
RU2676277C2 (ru) 2018-12-27
PT2945620T (pt) 2018-02-21
AU2018241168A1 (en) 2018-11-01
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
SI2945621T1 (sl) 2019-01-31
DK3284463T3 (da) 2019-10-28
AU2014207408A8 (en) 2015-08-27
IL259233A (en) 2018-07-31
CA2898443A1 (en) 2014-07-24
IL239906B (en) 2018-05-31
HK1216857A1 (en) 2016-12-09
TR201802211T4 (tr) 2018-03-21
TW201446242A (zh) 2014-12-16
SMT201900575T1 (it) 2019-11-13
US20200121633A1 (en) 2020-04-23
NZ748769A (en) 2020-05-29
RS59434B1 (sr) 2019-11-29
PL2945620T3 (pl) 2018-03-30
CN105073105A (zh) 2015-11-18
AU2018203240A1 (en) 2018-05-31
WO2014113700A9 (en) 2014-10-09
LT2945621T (lt) 2019-01-10
US20240066002A1 (en) 2024-02-29
BR112015017241B1 (pt) 2021-10-26
PT2945621T (pt) 2019-01-21
US20200163929A1 (en) 2020-05-28
HUE046722T2 (hu) 2020-03-30
AU2017200147B2 (en) 2018-07-05
US9586896B2 (en) 2017-03-07
AU2018241168B2 (en) 2020-04-02
PL3284463T3 (pl) 2019-12-31
SG10201802862WA (en) 2018-05-30
RS58174B1 (sr) 2019-03-29
CN110179777A (zh) 2019-08-30
TW201934120A (zh) 2019-09-01
RU2018143994A (ru) 2019-01-16
ES2705240T3 (es) 2019-03-22
LT3284463T (lt) 2019-11-11
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
BR112015017241A2 (pt) 2017-07-11
SG10201913286PA (en) 2020-02-27
CY1121480T1 (el) 2020-05-29
HRP20182144T1 (hr) 2019-03-08
IL239952A0 (en) 2015-08-31
ZA201505090B (en) 2016-10-26
SG10201913441RA (en) 2020-03-30
MX363843B (es) 2019-04-05
WO2014113700A1 (en) 2014-07-24
AU2014207408A1 (en) 2015-08-13
BR112015017251A2 (pt) 2017-07-11
US11786501B2 (en) 2023-10-17
ES2751922T3 (es) 2020-04-02
SG11201505567RA (en) 2015-09-29
KR102277165B1 (ko) 2021-07-14
CA2898445A1 (en) 2014-07-24
CN105073105B (zh) 2018-02-27
EP3284463A1 (en) 2018-02-21
US20180235927A1 (en) 2018-08-23
HRP20191919T8 (hr) 2021-10-01
TWI619491B (zh) 2018-04-01
HRP20191919T1 (hr) 2020-01-10
EP3427728A1 (en) 2019-01-16
US20210015784A1 (en) 2021-01-21
TWI686193B (zh) 2020-03-01
KR20150107853A (ko) 2015-09-23
US10245249B2 (en) 2019-04-02
MX2015009276A (es) 2015-10-30
US12186301B2 (en) 2025-01-07
US20170151210A1 (en) 2017-06-01
US8987326B2 (en) 2015-03-24
CY1122177T1 (el) 2020-11-25
EP3567031A1 (en) 2019-11-13
IL258882A (en) 2018-06-28
JP2016505044A (ja) 2016-02-18
AU2014207404A1 (en) 2015-08-13
HUE041861T2 (hu) 2019-06-28
CN108610312A (zh) 2018-10-02
HUE036589T2 (hu) 2018-07-30
JP2019089764A (ja) 2019-06-13
LT2945620T (lt) 2018-02-12
ZA201604798B (en) 2018-01-31
EP3284463B1 (en) 2019-07-24
JP2017125015A (ja) 2017-07-20
AU2014207408B2 (en) 2018-03-01
MX2015009269A (es) 2015-10-30
IL259233B (en) 2019-10-31
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
NZ709985A (en) 2020-05-29
EP2945620A1 (en) 2015-11-25
MX373176B (es) 2020-04-22
TWI712409B (zh) 2020-12-11
WO2014113696A1 (en) 2014-07-24
US9968584B2 (en) 2018-05-15
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
CN110179777B (zh) 2022-07-15
SI3284463T1 (sl) 2019-12-31
TW201442702A (zh) 2014-11-16
IL239952B (en) 2018-05-31
HRP20180121T1 (hr) 2018-02-23
CA2898443C (en) 2022-05-31
US20140206769A1 (en) 2014-07-24
BR112015017251B1 (pt) 2021-10-26
JP6656345B2 (ja) 2020-03-04
CN105142627B (zh) 2019-06-21
JP6449171B2 (ja) 2019-01-09
JP6533159B2 (ja) 2019-06-19
RU2015134583A (ru) 2017-02-22
US10548872B2 (en) 2020-02-04
CN105142627A (zh) 2015-12-09
SI2945620T1 (en) 2018-01-31
JP2019172682A (ja) 2019-10-10
US20190224159A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
NZ748771A (en) Pharmaceutical compositions comprising nitroxyl donors
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX2022010947A (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2017014613A (es) Compuestos de bencimidazol e imadazopiridin-carboximidamida que tienen actividad como inhibidores de indolamina 2,3-dioxigenasa.
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180036A1 (ar) أملاح لمثبطات فروبورتين جديدة
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
NZ708593A (en) Novel pyrazole derivative
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
NZ733313A (en) Indole derivatives as dengue viral replication inhibitors
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
BR112014014877A2 (pt) derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JAN 2022 BY CPA GLOBAL

Effective date: 20201203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JAN 2023 BY CPA GLOBAL

Effective date: 20211202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JAN 2024 BY CPA GLOBAL

Effective date: 20221202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JAN 2025 BY CPA GLOBAL

Effective date: 20231130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241205